Adieu to Aduhelm: Biogen Stops Marketing Antibody
The company announced it would halt its post-market trial and stop selling the drug; the rights to it now revert to Swiss company Neurimmune.
215 RESULTS
Sort By:
The company announced it would halt its post-market trial and stop selling the drug; the rights to it now revert to Swiss company Neurimmune.
Backed up, the cells never transitioned into a disease-associated state, shirking their plaque compaction and synapse protection duties.
In Alzheimer’s, Parkinson’s, and Lewy body dementia, phospholipid and cholesterol homeostasis are disrupted early on. Scientists are bringing new methods to bear on the problem.
In sleep-deprived mice, TREM2 signaling activated microglia in a dysfunctional way, hobbling their endolysosomes and keeping them from digesting Aβ plaques.
Dozens of structural features of the heart correlated with measures of regional volume, integrity of white-matter tracts, and functional connectivity within the brain.
A tiny PET study saw gliosis in putamen and striatum of some with persistent depression after COVID; larger health registry studies find scant evidence.
In a small open-label Phase 1/2 trial, Denali’s enzyme replacement therapy lowered neurofilament light in the cerebrospinal fluid by half and in serum by two-thirds.
In Kuopio, a collaborative tissue resource supplies the broadest swath of materials found anywhere for functional studies on ADRD genes. Think ABI3, APP, C9ORF72, GRN, PLCG2, TMEM106B—and more.
A new method for precisely localizing pathological tau in whole mouse brain finds that its spread follows network connections—but it seems to move up axons, not down.
First data from the Longitudinal Early-Onset Alzheimer’s Disease Study hints at what might cause this type of AD and how it unfolds.
The ability to quickly detect cerebral amyloid angiopathy and ARIA would make amyloid immunotherapy safer, but research in this area is just beginning.
At AAIC 2023, scientists tied clinical success to drug exposure, speed of plaque clearance, amyloid negativity.
Few people with Down's syndrome have cardiovascular risk factors, yet most develop cerebrovascular disease. Will this complicate anti-amyloid immunotherapy?
Together, the two immune-cell types deal a neurodegenerative blow more powerful than either can inflict alone.
The newly proposed scheme uses only amyloid and tau for diagnosis and staging. It establishes parallel tracks for fluid or imaging markers, and recognizes a clinical stage zero.